title: Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria.
abstract: OBJECTIVE
  To assess the effectiveness of angiotensin converting enzyme inhibition in preventing the development of diabetic nephropathy (albuminuria greater than 300 mg/24h).
  
  
  METHODS
  Open randomised controlled study of four years' duration.
  
  
  METHODS
  Outpatient diabetic clinic in tertiary referral centre.
  
  
  METHODS
  44 normotensive (mean blood pressure 127/78 (SD 12/10) mm Hg) insulin dependent diabetic patients with persistent microalbuminuria (30-300 mg/24h).
  
  
  METHODS
  The treatment group (n = 21) was initially given captopril (25 mg/24 h). The dose was increased to 100 mg/24 h during the first 16 months and thiazide was added after 30 months. The remaining 23 patients were left untreated.
  
  
  METHODS
  Albuminuria, kidney function, development of diabetic nephropathy (albuminuria greater than 300 mg/24 h), and arterial blood pressure.
  
  
  RESULTS
  Clinical and laboratory variables were comparable at baseline. Urinary excretion of albumin was gradually reduced from 82 (66-106) to 57 (39-85) mg/24 h (geometric mean (95% confidence interval)) in the captopril treated group, whereas an increase from 105(77-153) to 166 (83-323) mg/24 h occurred in the control group (p less than 0.05). Seven of the untreated patients progressed to diabetic nephropathy, whereas none of the captopril treated patients developed clinical overt diabetic nephropathy (p less than 0.05). Systemic blood pressure, glomerular filtration rate, haemoglobin A1c concentration, and urinary excretion of sodium and urea remained practically unchanged in the two groups.
  
  
  CONCLUSIONS
  The findings suggest that angiotensin converting enzyme inhibition postpones the development of clinical overt diabetic nephropathy in normotensive insulin dependent diabetic patients with persistent microalbuminuria.
authors.affiliation: Hvidøre Hospital, Klampenborg, Denmark.
authors.forename: E R
authors.initials: ER
authors.lastname: Mathiesen
authors.forename: E
authors.initials: E
authors.lastname: Hommel
authors.forename: J
authors.initials: J
authors.lastname: Giese
authors.forename: H H
authors.initials: HH
authors.lastname: Parving
mesh_terms: D000293:Adolescent; D000328:Adult; D000419:Albuminuria / Q000188:drug therapy* / Q000209:etiology; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000150:complications* / Q000503:physiopathology; D003928:Diabetic Nephropathies / Q000517:prevention & control*; D005260:Female; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D002216:Captopril